Study
From Broad-Spectrum Senolysis to Precision Reprogramming: Senolytics Enter Next Generation
Nature Aging review charts the shift from first-generation senolytics (dasatinib+quercetin) to precision senotherapeutics.
Summary Are quercetin and fisetin proven anti-aging treatments? Show / hide ↓
Researchers reviewed how senolytics, drugs that remove damaged aging cells, have developed. They compared older approaches such as quercetin, fisetin, and a drug combination with newer targeted treatments and partial reprogramming, which aims to restore cell function without fully changing a cell’s identity. The review said older treatments can affect healthy cells because they work broadly. It did not enroll people or report a new human result, and several human trials are still underway.
What this means for you: Do not buy quercetin or fisetin expecting proven anti-aging benefits. This review describes promising research but does not show that supplement versions work safely or effectively in people.
early evidenceA review published in Nature Aging traced the evolution of senolytic research from early first-generation compounds (navitoclax, dasatinib+quercetin combination) to next-generation approaches including precision senotherapeutics and partial reprogramming. The review noted that first-generation senolytics had broad off-target effects, and the field is moving toward more targeted approaches. For supplement consumers, the relevance is that quercetin and fisetin, which are available as supplements, are first-generation senolytics with broad mechanisms. The review suggests that the next generation may be more targeted and effective, but also that the current supplement-grade senolytics may have limitations that more precise approaches could overcome. The dasatinib+quercetin combination remains the most-studied senolytic in human trials, with the SToMP-MS and other trials ongoing.
Early first-generation senolytics including navitoclax and the dasatinib-quercetin combination are being superseded by precision approaches.
Review article, not original research. No new clinical data. Supplement-grade senolytics (quercetin, fisetin) may be less effective than pharmaceutical approaches.
From this page back to the goal it moves.
Cited by
3 encyclopedia entries reference this study.